Analysts Set MedEquities Realty Trust Inc (MRT) Price Target at $12.50

MedEquities Realty Trust Inc (NYSE:MRT) has earned an average rating of “Buy” from the seven analysts that are presently covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $12.50.

A number of equities analysts have recently issued reports on MRT shares. Zacks Investment Research cut MedEquities Realty Trust from a “buy” rating to a “hold” rating in a report on Wednesday, January 3rd. ValuEngine upgraded MedEquities Realty Trust from a “hold” rating to a “buy” rating in a report on Friday, December 1st. Citigroup cut their price objective on MedEquities Realty Trust from $12.00 to $10.00 and set a “neutral” rating for the company in a report on Thursday, March 1st. B. Riley set a $13.00 price objective on MedEquities Realty Trust and gave the stock a “buy” rating in a report on Thursday, February 22nd. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $14.00 price objective on shares of MedEquities Realty Trust in a report on Wednesday, February 21st.

How to Become a New Pot Stock Millionaire

MRT stock traded down $0.07 during trading on Wednesday, reaching $10.09. The company had a trading volume of 134,575 shares, compared to its average volume of 159,186. MedEquities Realty Trust has a twelve month low of $9.67 and a twelve month high of $13.06. The stock has a market capitalization of $323.97, a PE ratio of 15.77 and a beta of 0.21.

MedEquities Realty Trust (NYSE:MRT) last posted its quarterly earnings data on Wednesday, February 21st. The financial services provider reported $0.18 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.13). MedEquities Realty Trust had a return on equity of 5.99% and a net margin of 34.96%. The firm had revenue of $16.23 million during the quarter, compared to analysts’ expectations of $16.31 million. During the same quarter in the previous year, the company posted ($0.06) earnings per share. MedEquities Realty Trust’s revenue for the quarter was up 13.8% compared to the same quarter last year. equities analysts anticipate that MedEquities Realty Trust will post 1.21 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 5th. Stockholders of record on Monday, February 19th were issued a $0.21 dividend. This represents a $0.84 dividend on an annualized basis and a dividend yield of 8.33%. The ex-dividend date of this dividend was Thursday, February 15th. MedEquities Realty Trust’s payout ratio is currently 131.25%.

A number of hedge funds have recently modified their holdings of the stock. Parametric Portfolio Associates LLC boosted its holdings in MedEquities Realty Trust by 4.4% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 40,531 shares of the financial services provider’s stock valued at $512,000 after acquiring an additional 1,704 shares during the period. Sumitomo Mitsui Trust Holdings Inc. boosted its holdings in MedEquities Realty Trust by 29.7% during the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 26,829 shares of the financial services provider’s stock valued at $315,000 after acquiring an additional 6,143 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in MedEquities Realty Trust by 42.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 26,586 shares of the financial services provider’s stock valued at $335,000 after acquiring an additional 7,923 shares during the period. LSV Asset Management purchased a new stake in MedEquities Realty Trust during the 4th quarter valued at about $103,000. Finally, JPMorgan Chase & Co. purchased a new stake in MedEquities Realty Trust during the 3rd quarter valued at about $118,000. Institutional investors own 92.76% of the company’s stock.

WARNING: This report was first published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this report on another domain, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be accessed at https://www.tickerreport.com/banking-finance/3296150/analysts-set-medequities-realty-trust-inc-mrt-price-target-at-12-50.html.

MedEquities Realty Trust Company Profile

MedEquities Realty Trust, Inc is a real estate investment trust (REIT). The Company invests in a diversified mix of healthcare properties and healthcare-related real estate debt investments. The Company invests primarily in real estate across the acute and post-acute spectrum of care. It focuses on investing in various types of healthcare properties, including acute care hospitals; skilled nursing facilities; short-stay surgical and specialty hospitals, which focus on orthopedic, heart and other dedicated surgeries and specialty procedures; dedicated specialty hospitals, such as inpatient rehabilitation facilities, long-term acute care hospitals and facilities providing psychiatric care; physician clinics; diagnostic facilities; outpatient surgery centers, and facilities that support these services, such as medical office buildings.

Analyst Recommendations for MedEquities Realty Trust (NYSE:MRT)

Receive News & Ratings for MedEquities Realty Trust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MedEquities Realty Trust and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Micro Focus  Earning Somewhat Favorable Press Coverage, Study Finds
Micro Focus Earning Somewhat Favorable Press Coverage, Study Finds
Randgold Resources  Given Daily News Impact Rating of 0.11
Randgold Resources Given Daily News Impact Rating of 0.11
Camden Property Trust  Getting Positive News Coverage, Report Finds
Camden Property Trust Getting Positive News Coverage, Report Finds
Zacks: Brokerages Expect Spark Therapeutics  Will Announce Quarterly Sales of $53.82 Million
Zacks: Brokerages Expect Spark Therapeutics Will Announce Quarterly Sales of $53.82 Million
USDe  Price Hits $0.0002 on Exchanges
USDe Price Hits $0.0002 on Exchanges
DigiPulse  Reaches 24 Hour Trading Volume of $211,967.00
DigiPulse Reaches 24 Hour Trading Volume of $211,967.00


© 2006-2018 Ticker Report. Google+.